10:34 AM EST - QLT Inc. : has reported a 2007 net loss of US$110 million as rising sales of its Eligard prostate-cancer treatment failed to offset fading revenue from the Visudyne eye drug. QLT, which keeps its accounts in U.S. dollars, said Thursday that full-year revenue slumped 26.9 percent to $127.9 million, compared with $175 million in 2006. QLT Inc.
shares T.QLT are trading up 11 cents at $3.84.
